Institutional members access full text with Ovid®

Share this article on:

Pediatric Germ Cell Tumor: An Experience with BEP

Kapoor Gauri M.D.; Advani, S. H. M.D., F.I.C.P.; Nair, C. N. D.C.H., Ph.D.; Pai, S. K. M.D.; Kurkure, P. A. M.D.; Nair, Reena M.D.; Saikia, T. K. M.D.; Vege, D. M.D.; Desai, P. B. M.S., F.R.C.S.
Journal of Pediatric Hematology/Oncology: November 1995


This study is an analysis of our experience with bleomycin, etoposide, and cisplatin (BEP) chemotherapy, in pediatric germ cell tumors (GCTs).

Patients and Methods

The study included all children (age <16 years) who were registered between May 1988 and May 1993 with a histologically confirmed diagnosis of GCT and received BEP chemotherapy. In addition to the clinicopathological features, the response rate, survival rate, and toxicity were analyzed.


There was a total of 56 patients, of whom 22 had an ovarian tumor and 17 each had a testicular or an extragonadal tumor. Histologically, endodermal sinus tumor was the most common type (62%). Tumor markers were increased in 89% (50 of 56). Complete responses were observed in 89.1% (49 of 55) and partial responses in 10.9% (6 of 55) of the evamable patients. Five-year actuarial survival was 83% and progression free survival was 93%. Median follow-up was 18 months. Median survival is not yet reached. The chemotherapy was well tolerated.


From the present report, it is apparent that BEP chemotherapy is very effective and well tolerated in children with GCT. The data probably suggests that conservative surgery, when combined with effective chemotherapy, can result in cure of the majority of children with GCTs.

© Lippincott-Raven Publishers.